Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
636
Recruiting, any sponsor type, condition "pancreatic"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting636
- Completed2,034
636 trials
Showing 1 to 25, recently updated first.
Haihua YuanAcademic, hospital or other
NCT07631871 · 10 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2029
Drug: Zanidatamab · For: Neoplasms; Solid Tumors; HER2 Positive Solid Tumor and 7 more
Sites: Shanghai, China
- GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant AscitesPivotal-lookingRecruiting
Kyushu UniversityAcademic, hospital or other
NCT05438459 · 176 participants (planned) · Start Jun 8, 2022 · Primary completion Mar 31, 2032
Drug: GAIA-102; GAIA-102 and 6 more · For: Gastric Cancer; Pancreatic Cancer
Sites: Fukuoka, Japan
National Cancer Institute (NCI)NIH
NCT04222413 · 116 participants (planned) · Start Oct 27, 2020 · Primary completion Dec 31, 2027
Drug: Metarrestin · For: Advanced Solid Tumors; Metastatic Pancreatic Cancer; Pediatric Solid Tumor and 3 more
Sites: Fairway, Kansas; Bethesda, Maryland
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPivotal-lookingRecruiting
Pierre Fabre MedicamentIndustry
NCT03394365 · 115 participants (planned) · Start Dec 29, 2017 · Primary completion May 31, 2030
Drug: tabelecleucel · For: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Solid Organ Transplant Complications; Lymphoproliferative Disorders and 2 more
Sites: Duarte, California; La Jolla, California; Loma Linda, California · 72 sites in all
IDEAYA BiosciencesIndustry
NCT07277413 · 570 participants (planned) · Start Mar 4, 2026 · Primary completion Apr 30, 2028
Drug: IDE892; IDE397 and 1 more · For: Bladder Cancer; Mesothelioma; Pleural Mesothelioma and 5 more
Sites: Goodyear, Arizona; Phoenix, Arizona; Duarte, California · 26 sites in all
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
Kestrel Therapeutics, Inc.Academic, hospital or other
NCT07458347 · 545 participants (planned) · Start Apr 21, 2026 · Primary completion Apr 2028
Drug: KST-6051; Gemcitabine/nab-paclitaxel and 6 more · For: KRAS-mutant Non-small Cell Lung Cancer (NSCLC); KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC); KRAS-mutant Colorectal Cancer (CRC) and 1 more
Sites: Los Angeles, California; Sarasota, Florida; Tampa, Florida · 9 sites in all
Haihua YuanAcademic, hospital or other
NCT07631884 · 15 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2028
Drug: Trastuzumab Rezetecan · For: Solid Tumors; Neoplasms (Cancer / Tumors); Advanced Malignant Solid Neoplasm and 13 more
Sites: Shanghai, China
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT07948070 · 40 participants (planned) · Start Jun 2, 2026 · Primary completion Jul 2028
Drug: GKPTZ-01 in Combination with Adjuvant Chemotherapy; GKPTZ-01 and 1 more · For: Pancreatic Cancer
Sites: Tianjin, China
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruiting
National Cancer Institute (NCI)NIH
NCT06503146 · 320 participants (planned) · Start Sep 9, 2025 · Primary completion Jun 1, 2028
Drug: [18F]FAPI-74; [18F]FDG · For: Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma and 7 more
Sites: Bethesda, Maryland
RasCal Therapeutics, Inc.Industry
NCT04678648 · 134 participants (planned) · Start Mar 3, 2021 · Primary completion Mar 16, 2027
Drug: RSC-1255 Dose Escalation; RSC-1255 Dose Expansion · For: Advanced Malignant Solid Neoplasm; RAS Mutation; Lung Cancer and 3 more
Sites: Los Angeles, California; Denver, Colorado; Nashville, Tennessee
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07488676 · 150 participants (planned) · Start May 4, 2026 · Primary completion Jul 31, 2029
Drug: ASP546C · For: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 35 sites in all
National Cancer Institute (NCI)NIH
NCT05372614 · 58 participants (planned) · Start Oct 5, 2022 · Primary completion Jul 17, 2028
Drug: Neratinib Maleate; Trastuzumab Deruxtecan · For: Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8 and 3 more
Sites: Duarte, California; Irvine, California; Lancaster, California · 18 sites in all
- Polymeric Micellar Paclitaxel for Metastatic Pancreatic CancerPivotal-lookingRecruiting
Shanghai Yizhong Pharmaceutical Co., Ltd.Industry
NCT06752811 · 416 participants (planned) · Start Feb 5, 2025 · Primary completion Jul 1, 2027
Drug: paclitaxel polymeric micelles for injection; Gemcitabine Hydrochloride for Injection and 2 more · For: Pancreatic Cancer Metastatic
Sites: Nanjing, China; Shanghai, China
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT04858334 · 152 participants (planned) · Start Jun 22, 2021 · Primary completion Oct 31, 2027
Drug: Olaparib; Placebo Administration · For: Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma and 4 more
Sites: Anchorage, Alaska; Fairbanks, Alaska; Kingman, Arizona · 457 sites in all
Peking University Cancer Hospital & InstituteAcademic, hospital or other
NCT05321316 · 40 participants (planned) · Start May 31, 2025 · Primary completion Dec 2026
Drug: 18F-FDG · For: Urothelial Carcinoma; Breast Cancer; Lung Cancer and 3 more
Sites: Beijing, China
- THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIALPivotal-lookingRecruiting
Hellenic Institute for the Study of SepsisAcademic, hospital or other
NCT07813767 · 398 participants (planned) · Start Oct 1, 2026 · Primary completion Sep 2028
Drug: Meropenem Infusion; Sodium Chloride (NaCl) 0.9 % · For: Sepsis
Sites: Athens, Greece; Piraeus, Greece; Ioannina, Greece · 10 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06172478 · 890 participants (planned) · Start Feb 26, 2024 · Primary completion Nov 19, 2030
Drug: HER3-DXd · For: Advanced Solid Tumor; Melanoma; Head and Neck Cancer and 11 more
Sites: Duarte, California; New Haven, Connecticut; Kissimmee, Florida · 97 sites in all
National Cancer Center, JapanGovernment (non-federal)
NCT06159478 · 32 participants (planned) · Start Jun 30, 2023 · Primary completion Feb 28, 2028
Drug: Binimetinib 15 MG · For: Low-grade Glioma; Pancreatic Cancer
Sites: Kashiwa, Japan; Fukuoka, Japan; Sapporo, Japan · 6 sites in all
University of ArizonaAcademic, hospital or other
NCT07627191 · 30 participants (planned) · Start Oct 7, 2026 · Primary completion Jun 30, 2028
Drug: GLP1-RA (semaglutide) · For: Pancreatic Cancer; Colorectal Cancer; Hepatocellular Carcinoma
Sites: Tucson, Arizona
Johns Hopkins UniversityAcademic, hospital or other
NCT05704036 · 75 participants (planned) · Start May 2, 2023 · Primary completion Jan 2028
Drug: Transdermal estrogen; Progesterone · For: Cystic Fibrosis; Hypoestrogenism
Sites: Baltimore, Maryland
- A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.Recruiting
PfizerPfizer (PFE)
NCT07903415 · 280 participants (planned) · Start Nov 5, 2026 · Primary completion Jan 26, 2031
Drug: PF-08098488 · For: Pancreatic Ductal Adenocarcinoma; Esophageal Cancer; Carcinoma, Non-Small-Cell Lung (NSCLC) and 2 more
Sites: Grand Rapids, Michigan; Nashville, Tennessee; San Antonio, Texas · 4 sites in all
- A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D MutationRecruiting
Tyligand Pharmaceuticals (Suzhou) LimitedIndustry
NCT06385925 · 570 participants (planned) · Start Apr 29, 2024 · Primary completion Oct 30, 2027
Drug: TSN1611; TSN1611 and 3 more · For: Malignant Neoplasm
Sites: Houston, Texas; San Antonio, Texas; Fairfax, Virginia · 24 sites in all
- Prospective Randomized Trial Protocol for Duration of Post-Operative Tazocin Treatment After Whipple OperationPivotal-lookingRecruiting
Tel-Aviv Sourasky Medical CenterGovernment (non-federal)
NCT07939152 · 200 participants (planned) · Start Mar 9, 2025 · Primary completion Dec 31, 2028
Drug: piperacillin-tazobactam · For: Post Operative Surgical Site Infection; Pancreatic Leak
Sites: Tel Aviv, Israel
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07491445 · 900 participants (planned) · Start Mar 9, 2026 · Primary completion Apr 2028
Drug: daraxonrasib; gemcitabine and 1 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 106 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.